Gubra
  • Services
    • Liver (NASH)
    • Kidney
    • Heart
    • Obesity
    • Diabetes
    • 3D Imaging
    • Customized services
    • Lung (IPF)
    • Intestine (IBD)
  • Discovery
    • Target Discovery
    • Drug Discovery
    • StreaMLine
  • Capabilities
    • In vivo pharmacology
    • Histology & Stereology
    • Imaging
    • NGS & Bioinformatics
    • Ex vivo assays
    • Drug Profiling
    • Peptide Chemistry
    • Gubra video gallery
  • Publications
  • Careers
  • About us
    • Leadership
    • Events
    • News
    • Webinars
    • CSR
Select Page

2018 ADA_dbdb UNx_2018-06-15, Unbiased Stereological Quantification of Key Features of Diabetic Nephropathy

2018 ADA_dbdb UNx_2018-06-15, Unbiased Stereological Quantification of Key Features of Diabetic Nephropathy

Recent Posts

  • Ferring Pharmaceuticals and Gubra announce collaboration within inflammatory bowel disease (IBD)
  • Gubra once more awarded EY Entrepreneur Of The Year, Region Zealand.
  • Gubra strengthens Board of Directors with two international appointments
  • Gubra reports record high revenue and earnings in 2021 and strengthens Board of Directors and Executive Management with new appointments
  • Gubra ApS and Silence Therapeutics plc collaborate to develop RNAi therapies against novel liver-directed targets from Gubra’s streaMLine platform

Recent Comments

    Archives

    • November 2022
    • October 2022
    • September 2022
    • May 2022
    • February 2022
    • January 2022
    • September 2021
    • August 2021
    • May 2021
    • March 2021
    • December 2020
    • June 2020
    • May 2020
    • March 2020
    • October 2019
    • June 2019
    • May 2019
    • June 2018
    • September 2017
    • August 2017
    • June 2016
    • September 2013

    Categories

    • News
    • Press Release
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Services
    • Company
    • Careers
    • Contact
    • Privacy policy
    © 2023 Gubra
    Manage Cookie Consent
    We use cookies to optimize our website and our service.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage vendors Read more about these purposes
    Preferences
    {title} {title} {title}

      Gubra Services

      Liver (NASH)

      Benefit from our extensive know-how in NASH and test your compound in our validated DIO NASH mouse models.

      Learn more
      Kidney

      Check out our novel rodent models of diabetic nephropathy.

      Learn more
      3D Imaging

      Use quantitative light-sheet fluoresence microscopy to validate pre-clinical endpoints.

      Learn more
      Obesity

      Tap into our vast scientific experience with diet-induced obesity (DIO) models and other commercially available models.

      Learn more
      Heart (CVD)

      Check out our novel rodent models of cardiovascular disease.

      Learn more
      CNS

      Check out our capabilities in neurodegenerative diseases.

      Learn more
      Diabetes

      Qualify and advance your assessment of novel compounds to treat type 2 diabetes and diabetic complications.

      Learn more
      Lung (IPF)

      Check out our services within lung diseases.

      Learn more
      Intestine (IBD)

      Check out our novel rodent models of inflammatory bowel disease.

      Learn more